Wells Fargo & Company Petros Pharmaceuticals, Inc. Transaction History

Wells Fargo & Company

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$0.47 - $5.1 $4 - $45	9 Added 10.0%	99 $0
Q2 2022 Aug 12, 2022	BUY	$0.68 - $1.49 $4 - $10	7 Added 8.43%	90 $0
Q1 2022 May 16, 2022	BUY	$1.07 - $3.36 $24 - $77	23 Added 38.33%	83 $0
Q4 2021 Feb 14, 2022	BUY	$1.33 - $4.09 $25 - $77	19 Added 46.34%	60 $0
Q3 2021 Nov 15, 2021	BUY	$1.82 - $3.2 $23 - $41	13 Added 46.43%	41 $0
Q1 2021 May 13, 2021	BUY	$2.85 - $4.6 $5 - $9	2 Added 7.69%	28 $0
Q4 2020 Feb 09, 2021	BUY	$3.24 - $4.68 $84 - $121	26 New	26 $0

Ticker PTPI
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 20,708,000
Market Cap $6.42M
Description
Petros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men's health therapeutics. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also develops and commercializes H100, a patented topical formulation candidate for th...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.